Rovi and Recordati Deemed Top Picks By Analyst
The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.
You may also be interested in...
Introducing its Enoxaparin Becat biosimilar in both Spain and France during September this year – in the latter market through partner Biogaran – enabled Laboratorios Farmacéuticos Rovi to report turnover from the low molecular weight heparin (LMWH) of €7.8 million (US$8.9 million) in the third quarter, and €16.7 million in the first nine months, of this year. The Spanish firm has also just rolled out Becat in Austria and Latvia.
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.
The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.